Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non‐valvular atrial fibrillation from the RE‐LY trial: reply to a rebuttal

See also Liesenfled K‐H, Lehr T, Dansirikul C, Reilly PA, Connolly SJ, EzekowitzMD, Yusuf S,Wallentin L, Haertter S, Staab A. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non‐valvular atrial fibrillation from the RE‐LY trial. J Thromb Haemost 2011; 9: 2168–75; and Patel JP, Green B, Patel RK, Davies JG, Arya R. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non‐valvular atrial fibrillation from the RE‐LY trial: a rebuttal. This issue, pp 500–2.

[1]  T. Lehr,et al.  Dabigatran Etexilate in Atrial Fibrillation Patients With Severe Renal Impairment: Dose Identification Using Pharmacokinetic Modeling and Simulation , 2012, Journal of clinical pharmacology.

[2]  T. Lehr,et al.  A combined pharmacometric analysis of dabigatran etexilate in healthy volunteers and patients with atrial fibrillation or undergoing orthopaedic surgery , 2012, Thrombosis and Haemostasis.

[3]  R. Arya,et al.  Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non‐valvular atrial fibrillation from the RE‐LY trial: a rebuttal , 2012, Journal of thrombosis and haemostasis : JTH.

[4]  S. Yusuf,et al.  Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non‐valvular atrial fibrillation from the RE‐LY trial , 2011, Journal of thrombosis and haemostasis : JTH.

[5]  K. Rathgen,et al.  Influence of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate , 2010, Clinical pharmacokinetics.

[6]  T. Ebner,et al.  The Metabolism and Disposition of the Oral Direct Thrombin Inhibitor, Dabigatran, in Humans , 2008, Drug Metabolism and Disposition.

[7]  K. Rathgen,et al.  Pharmacokinetics and Pharmacodynamics of the Direct Oral Thrombin Inhibitor Dabigatran in Healthy Elderly Subjects , 2008, Clinical pharmacokinetics.

[8]  K. Rathgen,et al.  The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. , 2007, British journal of clinical pharmacology.

[9]  I. Trocóniz,et al.  Population Pharmacokinetic Analysis of the New Oral Thrombin Inhibitor Dabigatran Etexilate (BIBR 1048) in Patients Undergoing Primary Elective Total Hip Replacement Surgery , 2007, Journal of clinical pharmacology.

[10]  Stuart L. Beal,et al.  Interaction between structural, statistical, and covariate models in population pharmacokinetic analysis , 1994, Journal of Pharmacokinetics and Biopharmaceutics.

[11]  J. Samet,et al.  Food and Drug Administration , 2007, BMJ : British Medical Journal.

[12]  E N Jonsson,et al.  Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. , 1999, Computer methods and programs in biomedicine.

[13]  M. H. Gault,et al.  Prediction of creatinine clearance from serum creatinine. , 1975, Nephron.